Exposed: 10 CENT Crypto to Explode April 20th?

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Troy Ignelzi Biography and Net Worth

CFO of Karuna Therapeutics

Troy A. Ignelzi joined Karuna Therapeutics as Chief Financial Officer in March 2019, bringing more than 25 years of experience supporting companies in finance, business development and operations. He joins Karuna from scPharmaceuticals where he, in his role as Chief Financial Officer, helped oversee development from a privately-held clinical-stage company to a publicly-traded biopharma preparing for commercial launch. Prior to scPharmaceuticals, Mr. Ignelzi was a senior executive at Juventas Therapeutics, Esperion Therapeutics, and Insys Therapeutics, helping raise public/private capital, expand development pipelines through licensing/acquisition and advancing critical therapies, several of which are currently approved by the FDA. He also brings relevant commercial experience, having launched and promoted CNS therapies while at Eli Lilly. Mr. Ignelzi is a member of the board of directors at Vedanta Biosciences and CinCor.

Mr. Ignelzi holds a bachelor’s degree in Accounting from Ferris State University.

What is Troy A. Ignelzi's net worth?: The estimated net worth of Troy A. Ignelzi is at least $10.06 million as of August 22nd, 2023. Mr. Ignelzi owns 30,487 shares of Karuna Therapeutics stock worth more than $10,055,527 as of April 26th. This net worth evaluation does not reflect any other investments that Mr. Ignelzi may own. Learn More about Troy A. Ignelzi's net worth.
How do I contact Troy A. Ignelzi?: The corporate mailing address for Mr. Ignelzi and other Karuna Therapeutics executives is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. Karuna Therapeutics can also be reached via phone at (857) 449-2244 and via email at [email protected]. Learn More on Troy A. Ignelzi's contact information.
Has Troy A. Ignelzi been buying or selling shares of Karuna Therapeutics?: Troy A. Ignelzi has not been actively trading shares of Karuna Therapeutics during the last ninety days. Most recently, Troy A. Ignelzi sold 1,500 shares of the business's stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $175.12, for a transaction totalling $262,680.00. Following the completion of the sale, the chief financial officer now directly owns 30,487 shares of the company's stock, valued at $5,338,883.44. Learn More on Troy A. Ignelzi's trading history.
Who are Karuna Therapeutics' active insiders?: Karuna Therapeutics' insider roster includes Stephen Brannan (Insider), James Healy (Director), Troy Ignelzi (CFO), Jeffrey Jonas (Director), Andrew Miller (COO), Laurie Olson (Director), Atul Pande (Director), Steven Paul (CEO), and Heather Preston (Director). Learn More on Karuna Therapeutics' active insiders.
Are insiders buying or selling shares of Karuna Therapeutics?: In the last twelve months, insiders at the sold shares 12 times. They sold a total of 89,119 shares worth more than $20,412,131.47. The most recent insider tranaction occured on March, 8th when insider Stephen K Brannan sold 5,000 shares worth more than $1,591,700.00. Insiders at Karuna Therapeutics own 13.2% of the company. Learn More about insider trades at Karuna Therapeutics.
Information on this page was last updated on 3/8/2024.

Troy A. Ignelzi Insider Trading History at Karuna Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/22/2023	Sell	1,500	$175.12	$262,680.00	30,487
5/23/2023	Sell	9,000	$223.41	$2,010,690.00	30,487
1/18/2023	Sell	200	$200.14	$40,028.00	21,837
11/15/2022	Sell	16,500	$225.85	$3,726,525.00	9,970
10/3/2022	Sell	4,100	$231.18	$947,838.00	10,370
9/30/2022	Sell	10,500	$228.86	$2,403,030.00	14,470
8/9/2022	Sell	16,500	$227.83	$3,759,195.00	24,970
4/21/2022	Sell	40	$134.46	$5,378.40	24,970
4/19/2022	Sell	3,500	$130.81	$457,835.00	24,970
2/15/2022	Sell	1,500	$111.14	$166,710.00
11/8/2021	Sell	13,500	$152.32	$2,056,320.00
6/16/2021	Sell	2,600	$129.31	$336,206.00	15,248
6/14/2021	Sell	900	$132.52	$119,268.00	15,248
5/12/2021	Sell	200	$120.00	$24,000.00	20,000
5/10/2021	Sell	7,000	$110.07	$770,490.00	20,000
1/8/2021	Sell	8,000	$104.49	$835,920.00	21,000
11/9/2020	Sell	9,318	$105.48	$982,862.64	5,564
11/6/2020	Sell	564	$108.15	$60,996.60	5,564
9/8/2020	Sell	2,000	$73.30	$146,600.00	7,000
7/8/2020	Sell	8,000	$98.74	$789,920.00	6,000
6/15/2020	Sell	6,000	$89.75	$538,500.00	2,000
5/8/2020	Sell	7,500	$83.38	$625,350.00	7,500

Troy A. Ignelzi Buying and Selling Activity at Karuna Therapeutics

Karuna Therapeutics Company Overview

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of depressive disorder. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $329.83

$329.83

50 Day Range

MA: $325.43

$313.97

$329.83

2 Week Range

Now: $329.83

$158.38

$329.99

Volume

5 shs

Average Volume

832,048 shs

Market Capitalization

$12.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

Exposed: 10 CENT Crypto to Explode April 20th?

From True Market Insiders | Ad